Belgiumlund

LEUVEN, Belgium and LUND, Sweden - - Recruitment of 315 Patients Completed Ahead of Schedule - Results Anticipated in the second quarter of 2010 ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce that they have completed recruitment of their Phase II trial of TB-402 ahead of schedule.

LEUVEN, Belgium and LUND, Sweden - ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce that they have started recruitment of a second cohort of patients for their Phase II trial of TB-402.